Manila Times Business
High-Precision Base-Editing Therapy Demonstrates Durable VOC-Free Efficacy and Favorable Safety in Sickle Cell Disease
CorrectSequence Therapeutics Reports Positive 15-Month Follow-Up Data for CS-206 SHANGHAI, June 2, 2026 /PRNewswire/ -- CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical-stage biotechnology company pioneering transformer Base Editing (tBE) technology for severe diseases, announced that the first sickle cell disease (SCD) patient being treated in China with its high-precision base-editing therapy CS-206 has remained free of vaso-occlusive crises (VOCs) for more than 15 months follow
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Recharge Power and Energy Decarb Launch Joint Venture Targeting Australia's PV and BESS Market
2h ago
Xinhua Silk Road: Malaysia to continue deepening friendly cooperation with China, says deputy president of Malaysian Senate
2h ago
SEALSQ Acquires Miraex SA, Cementing Its Quantum Sovereign Vertical Stack and Quantum Orbital Space Cloud (QOSC)
2h ago
5 American cruise ship passengers leave Nebraska quarantine facility
2h ago